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Abstract We previously reported that BALB/cJ mouse-derived 
bone marrow-derived mast cells (BMMC) exhibited two 
sequential phases of prostaglandin D2 (PGD2) generation in 
response to Fce receptor I (FcERI) crosslinking and cytokine 
stimulation, the late phase of which was suppressed by an 
antibody raised against type IIA secretory phospholipase A2 
(sPLA2). Here we report that BMMC derived from C57BL/6J 
mice, which are genetically deficient in type IIA sPLA2, display 
both immediate and delayed PGD2 generation normally. Lysates 
of C57BL/6J-derived BMMC contained a Ca2+-dependent 
PLA2 that was absorbed to a column conjugated with anti-type 
IIA sPLA2 antibody and had a similar molecular mass of 14 kDa, 
as assessed by immunoblotting. Therefore we speculate that a 
sPLA2 similar to, but distinct from, type IIA sPLA2 would 
compensate for type IIA sPLA2 deficiency in C57BL/6J-derived 
BMMC. We found that the two type IIA-related sPLA2 family 
members, type V and type IIC sPLA2s, were expressed in 
BMMC as well as in rat mastocytoma RBL-2H3 cells. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
We have previously reported that BALB/cJ mouse-derived 
bone marrow-derived mast cells (BMMC) stimulated by 
FceRI crosslinking via IgE and antigen in the presence of 
specific accessory cytokines show two sequential prostaglan-
din D2 (PGD2) biosynthetic responses over time [1-6]. Imme-
diate PGD2 generation, occurring within a few minutes in 
response to a transient increase in cytoplasmic Ca2+ concen-
tration, is associated with transient perinuclear translocation 
and phosphorylation of cytosolic phospholipase A2 (cPLA2) 
[3,7,8]. The constitutively expressed cyclooxygenase (COX) 
isoform, COX-1, is the dominant enzyme involved in this 
rapid response, which converts arachidonic acid to PGH2, 
which in turn is metabolized to PGD2 via glutathione-depend-
ent PGD2 synthase [1,2,4,5]. Delayed PGD2 generation, oc-
curring over several hours of culture, is associated with the de 
novo induction and function of COX-2 [1,4,5]. The segregated 
processing of arachidonic acid implies a distinct supply or 
different intracellular conditions for the metabolism of arach-
idonic acid by the alternative COX isoforms. Based upon 
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observations that delayed PGD2 generation is accompanied 
by the induction of type IIA secretory PLA2 (sPLA2) tran-
script and is suppressed efficiently by an antibody against this 
enzyme, we speculated that type IIA sPLA2 is functionally 
linked to COX-2-dependent delayed PGD2 generation [6,9]. 
Moreover, earlier findings that histamine release from acti-
vated mast cells was sensitive to several inhibitors directed 
against type IIA sPLA2 led us to suggest that type IIA sPLA2 
is also involved in exocytosis [10]. 
However, the recent finding that several inbred mouse 
strains with natural disruption of the type IIA sPLA2 gene 
do not exhibit any apparent abnormality [11,12] has raised 
confusion about the role played by type IIA sPLA2 in mast 
cell activation. Here we show that BMMC derived from the 
C57BL/6J strain, possessing a disrupted type IIA sPLA2 gene, 
have the ability to elicit immediate and delayed PGD2 gener-
ation as well as exocytosis to a level comparable with that of 
BMMC derived from BALB/cJ strain, which expresses normal 
type IIA sPLA2. Importantly, lysates of C57BL/6J-derived 
BMMC contained sPLA2 immunoreactive with the anti-type 
IIA sPLA2 antibody, suggesting that sPLA2 related, but not 
identical, to type IIA sPLA2 would compensate for the func-
tion of type IIA sPLA2 in mast cells. RT-PCR analysis have 
revealed that cultured mast cells also express type V and IIC 
sPLA2s. 
2. Materials and methods 
2.1. Materials 
Recombinant mouse interleukin (IL)-ip was purchased from Gen-
zyme. Recombinant mouse c-kit ligand (KL), IL-10 and type IIA 
SPLA2 were obtained by expression in a baculovirus system as de-
scribed previously [1]. A rabbit polyclonal antibody against mouse 
type II SPLA2 was prepared as described previously [6]. A rabbit 
polyclonal antibody against mouse COX-2 was purchased from Cay-
man Chemical. Monoclonal IgE anti-trinitrophenyl (TNP) and TNP-
conjugated bovine serum albumin as an antigen were provided by Dr. 
J.P. Arm and H. Katz (Harvard Medical School, Boston, MA). As-
pirin was purchased from Sigma. 
2.2. Preparation and activation of BMMC 
BMMC were obtained from either BALB/cJ or C57BL/6J mouse 
bone marrow cells by culturing with 50% (v/v) WEHI-conditioned 
medium as a source of IL-3, as described previously [1]. Cells 
(107 cells/ml) were sensitized with 10 |ig/ml IgE anti-TNP for 30 min 
at 37°C, washed, and suspended in enriched medium [6] containing 
100 units/ml IL-10, 5 ng/ml IL-lp, 100 ng/ml KL and 20 ng/ml anti-
gen at 37°C. After various incubation periods, the supernatants were 
assayed for PGD2 and PGE2 using a PGD2 radioimmunoassay kit 
(Amersham) and a PGE2 enzyme immunoassay kit (Cayman), respec-
tively, and for p-hexosaminidase as a marker of exocytosis [2]. The 
cells were analyzed for protein expression. To assess only the delayed 
response, BMMC were pretreated with 10 (ig/ml aspirin for 2 h to 
inactivate COX-1, which is essential for immediate PGD2 generation, 
washed, and then activated as described previously [4]. 
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2.3. Immunoaffinity column 
BMMC were suspended in 10 mM Tris-HCl (pH 7.4) containing 
1 M NaCl and 1 mM EDTA at 1 X 107 cells/ml, disrupted by soni-
cation and centrifuged for 1 h at lOOOOOXg at 4°C. The pooled 
supernatants were applied to a formyl cellulofine (Seikagaku Kogyo) 
column that had been conjugated with the anti-mouse type IIA sPLA2 
antibody, as described previously [6]. The bound sPLA2 was eluted 
with 50 mM glycine-HCl buffer (pH 2.2). 
2.4. SDS-PAGElImmunoblotting 
Samples were separated by SDS-PAGE, electroblotted onto nitro-
cellulose membranes (Schleicher and Schuell) using a semi-dry blotter 
(MilliBlot-SDE system; Millipore), probed with antibodies against 
type IIA sPLA2 or COX-2, and visualized using an enhanced chemi-
luminescence Western blot analysis system (Amersham), as described 
previously [1,13]. 
2.5. sPLAg assay 
The standard reaction mixture consisted of 100 mM Tris-HCl, 
pH 9.0, 4 mM CaCl2, 2 uM l-palmitoyl-2-[
14C]linoleoyl-phosphatidyl-
ethanolamine (Amersham) and an aliquot of the samples. After in-
cubation for 30 min at 37°C, the released linoleic acid was extracted 
as described [13] and counted by a P-scintillation counter. 
2.6. Recombinant type IIC sPLA% 
The cDNA for type IIC sPLA2, obtained by RT-PCR from testis as 
described previously [6,14], was subcloned into pVL1393 (Pharmin-
gen) and transfected into Sf9 cells (Invitrogen) using a baculovirus 
system [1]. One week after the third transfection, the supernatants 
were collected and used as recombinant type IIC sPLA2. 
2.7. RT-PCR 
Specific primers for PCR for three sPLA2s were synthesized 
(Greiner Japan). Type IIA sPLA2 primers used were 5'-ATG AAG 
GTC CTC CTC CTG CTA G-3' and 5'-TCA GCA TTT GGG CTT 
CTT CC-3' [13], type IIC sPLA2 primers were 5'-ATG GAC CTC 
CTG GTC TCC TCA GG-3' and 5'-CTA GCA ATG AGT TTG 
TCC CTG C-3' [6], and type V sPLA2 primers were 5'-CAG GGG 
GCT TGC TAG AAC TCA A-3' and 5'-AAG AGG GTT GTA 
AGT CCA GAG G-3' [15]. The RT-PCR was carried out using a 
RNA PCR kit (AMV) version-2 (TaKaRa), according to the manu-
facturer's instructions, using 1 ug of total RNA from BMMC or rat 
mastocytoma RBL-2H3 as a template. Equal amounts of each RT 
product were PCR-amplified with ex Tag polymerase (TaKaRa) for 
30 cycles consisting of 30 s at 94°C, 30 s at 55°C and 30 s at 72°C. The 
amplified cDNA fragments were resolved on 1.5% (w/v) agarose gels 
and visualyzed by ethidium bromide. 
3. Results 
3.1. Mediator release from C57BLI6J-derived BMMC 
To assess the immediate response, BMMC derived from 
C57BL/6J and BALB/cJ mice (type IIA sPLA2 ( - ) and (+), 
respectively) were each sensitized with IgE and activated with 
antigen for 10 min. C57BL/6J- and BALB/cJ-derived BMMC 
generated 4.5 ± 1.5 and 3.1 ± 0.7 ng of PGD2 per 106 cells and 
released 33 ±8% and 28 ±5% of P-hexosaminidase, respec-
tively (rc = 2, mean±S.D.). 
To assess the delayed response, these BMMC were sensi-
tized with IgE for 2 h in the presence of aspirin to irreversibly 
inactivate preexisting COX-1 [4], and then activated with anti-
gen in the presence of KL, IL-10 and IL-lp, thus eliciting 
maximal delayed PGD2 generation without accompanying im-
mediate PGD2 generation. As shown in Fig. 1, BMMC from 
both strains produced PGD2 over 2-10 h, reaching a maximal 
level of ~ 10 ng/106 cells at 10 h, in parallel with the induc-
tion of COX-2 expression. PGE2 was produced only in min-
imal amounts by both strains. Thus, despite the lack of type 
IIA sPLA2, C57BL/6J-derived BMMC were capable of both 
immediate and delayed PGD2 generation and exocytosis to a 
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Fig. 1. Delayed PGD2 and PGE2 generation and COX-2 protein ex-
pression by BMMC derived from C57BL/6J (left) and BALB/cJ 
(right). BMMC (1 X 106 cells/ml) sensitized with IgE in the presence 
of aspirin were washed and then activated for the indicated periods 
with antigen in combination with the cytokine triad, KL, IL-10 and 
IL-ip. Supernatants and cells were taken for PGD2 (closed symbols) 
and PGE2 (open symbols) assays (mean±S.D.; n = 2) (A) and im-
munoblotting for COX-2 (B), respectively. 
level comparable with BALB/cJ-derived BMMC, which ex-
press type IIA sPLA2 normally. 
3.2. Detection of immunoreactive sPLAg in 
C57BLI6J-derived BMMC 
In order to search for the sPLA2-like activity in BMMC, 
lOOOOOXg supernatants of cell lysates were prepared from 
both strains and applied to an immunoaffinity column con-
jugated with anti-mouse type IIA sPLA2 antibody. Although 
the PLA2 activity hydrolyzing 2-linoleoyl-phosphatidyletha-
nolamine was undetectable in the flow-through fractions 
(data not shown), significant PLA2 activity, which was com-
parable to that in BALB/cJ-derived BMMC, was recovered 
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Fig. 2. Characterization of immunoreactive SPLA2S in BALB/cJ- and C57BL/6J-derived BMMC. (A) Immunoaffinity column chromatography. 
The lOOOOOXg supernatants of lysates of C57BL/6J (left) or BALB/cJ (right) BMMC (5X107 cell equivalents) were applied to an anti-type 
IIA sPLA2 antibody-conjugated cellulofine column, and sPLA2 activity bound to the column was eluted with 50 mM glycine-HCl buffer, 
pH 2.2. PLA2 activity after elution with glycine-HCl buffer is shown. (B) Immunoblotting. Fraction 13 in panel (A) of C57BL/6J BMMC was 
neutralized and incubated with anti-type IIA sPLA2 antibody-conjugated beads for 1 h at room temperature. The immunoprecipitate was sub-
jected to SDS-PAGE/imrnunoblotting using anti-type IIA SPLA2 antibody. Visualized bands with molecular masses of approximately 25, 50, 
and 75 kDa correspond to IgG light chain, heavy chain and their complex, respectively. (C) pH dependence of immunoreactive sPLA2 activ-
ities. SPLA2 activities of C57BL/6J and BALB/cJ BMMC [fraction 12 in panel (A)] were assayed under different pH conditions. A representa-
tive result of three independent experiments is shown. 
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from C57BL/6J-derived BMMC after elution of the bound 
proteins with an acidic buffer (Fig. 2A). The PLA2 immuno-
reactive with the anti-type IIA sPLA2 antibody in C57BL/6J-
derived BMMC (Fig. 2B) showed a molecular mass of ap-
proximately 14 kDa as visualized by immunoblotting. Both 
immunoreactive PLA2 activities in BALB/cJ- and C57BL/6J-
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Fig. 4. Detection of transcripts for various sPLA2s in cultured mast 
cells by RT-PCR. Expression of type IIA, IIC and V sPLA2s in 
BALB/cJ-derived BMMC and RBL-2H3 cells were detected after 30 
cycles of RT-PCR amplification. The fragment sizes (~430 bp) 
were consistent with the predicted sizes of each SPLA2 cDNA. Hy-
bridization with the specific cDNA probes confirmed that these 
bands indeed corresponded to the respective SPLA2S (data not 
shown). 
derived BMMC required millimolar order Ca2+ for enzymatic 
activity (data not shown). Thus, the ability to hydrolyze 2-li-
noleoyl-phosphatidylethanolamine, immunochemical prop-
erty, molecular mass and mM Ca2+ requirement all suggest 
that the PLA2 detected in C57BL/6J-derived BMMC is 
sPLA2-like enzyme. The pH profiles of the sPLA2 activities 
in both strains, in comparison to that of recombinant mouse 
type IIA sPLA2, is shown in Fig. 2C. sPLA2 detected in 
BALB/cJ-derived BMMC, as well as recombinant mouse 
type IIA sPLA2, showed optimal activity at pH 7.4, whereas 
that in C57BL/6J-derived BMMC had an optimal pH of 8-9. 
This difference, together with the genetic evidence [11,12], im-
plies that the immunoreactive sPLA2 detected in C57BL/6J-
derived BMMC is distinct from type IIA sPLA2. 
3.3. Comparison with type IIC sPLA^ 
We have recently reported that BALB/cJ-derived BMMC 
express the type IIC sPLA2 transcript, as assessed by RT-
PCR [6]. In order to clarify whether the immunoreactive 
sPLA2 detected in C57BL/6J-derived BMMC was identical 
to the type IIC enzyme, we prepared recombinant type IIC 
sPLA2 using a baculovirus system (Fig. 3A) and compared its 
properties with those of C57BL/6J-derived BMMC sPLA2. 
The activity of the baculovirus-expressed type IIC sPLA2 
was Ca2+-dependent, requiring millimolar order Ca2+ (data 
not shown), and was optimal at pH 9 (Fig. 3B). The specific 
activity of this enzyme was about one eighth that of recombi-
nant type IIA sPLA2 (data not shown). However, the anti-
type IIA sPLA2 antibody did not crossreact with recombinant 
type IIC PLA2, as demonstrated by immunoblotting (Fig. 3C) 
and immunoabsorption (Fig. 3D). Therefore most sPLA2 de-
tected in C57BL/6J-derived BMMC may differ from type IIC 
sPLA2. 
3.4. Detection of type V SPLA2 in cultured mast cells 
To assess the expression of type IIA-like sPLA2s in 
BMMC, RT-PCR was carried out using specific primers for 
type IIA, IIC or V sPLA2s. After 30 cycles of amplification, 
the expression of type IIA, IIC and V sPLA2s was clearly 
detected in BALB/cJ-derived BMMC (Fig. 4). Similarly, 
type IIA, IIC and V sPLA2s were detected in rat mastocytoma 
RBL-2H3 cells (Fig. 4), indicating that mast cells generally 
contain more than one sPLA2. While this experiment was in 
progress, the expression of type V, but not type IIC, sPLA2 
has been shown in C57BL/6J-derived BMMC [16]. We also 
observed the similar expression pattern of these sPLA2s in 
C57BL/6J-derived BMMC (data not shown). Thus, the ex-
pression of each sPLA2 appears to differ among mast cells 
obtained from different sources. 
4. Discussion 
We have previously reported the cloning of mouse type 
IIA sPLA2 from cytokine-stimulated BALB/cJ BMMC 
and its possible participation in COX-2-dependent delayed 
PGD2 generation on the basis of its marked suppression by 
an antibody against recombinant type IIA sPLA2 [6]. How-
ever, our present finding that type IIA sPLA2-deficient 
C57BL/6J-derived BMMC displayed PGD2 generation to 
an extent comparable with BALB/cJ-derived BMMC argues 
against the role of type IIA sPLA2 in mast cell activation. 
Bingham et al. [9] have also recently observed a similar 
phenomenon, and concluded that a sPLA2 distinct from 
type IIA sPLA2 may be responsible for delayed PGD2 gener-
ation. 
Detailed analysis of the PLA2 activity in BMMC lysates 
revealed that C57BL/6J-derived, type IIA sPLA2-deficient 
BMMC contained a sPLA2 immunochemically close to type 
IIA sPLA2 (Fig. 2A and B). The level of this enzyme activity 
was comparable with that of immunoreactive sPLA2 activity 
detected in BALB/cJ-derived BMMC (Fig. 2A), consistent 
with the fact that BMMC derived from both strains exhibited 
PGD2 generation to a similar extent (Fig. 1). Although 
sPLA2s in C57BL/6J- and BALB/cJ-derived BMMC were im-
munochemically indistinguishable, they differed significantly 
in their pH-dependence; the former preferred alkaline pH 
and the latter was most active at neutral pH (Fig. 2C). Neu-
tral pH preference was also observed in recombinant type IIA 
sPLA2, consistent with its expression in BALB/cJ-derived 
BMMC. We previously reported that rat mastocytoma 
RBL-2H3 cells expressed at least three PLA2 enzymes, includ-
ing cPLA2, type IIA sPLA2 and an unknown PLA2 with 
chromatographic behaviors similar to type IIA sPLA2 [17]. 
Fonteh et al. [18] also demonstrated the presence of two 
type IIA sPLA2-like enzymes in BMMC derived from CBA/ 
J mice. Collectively, these results suggest that C57BL/6J-de-
rived BMMC express the sPLA2-like enzyme, which can sub-
stitute for type IIA sPLA2 to regulate mast cell function, 
thereby reflecting the redundancy of sPLA2 family members. 
Alternatively, the sPLA2-like enzyme, rather than type IIA 
Fig. 3. Characteristics of recombinant type IIC sPLA2 expressed by Sf9 cells. (A) Release of type IIC sPLA2 activity from baculovirus-infected 
Sf9 cells. Columns 1, 2, and 3 correspond to cells without transfection, cells transfected with control vector, and cells transfected with type IIC 
sPLA2, respectively. The supernatants were collected and assayed for PLA2 activity. (B) pH profile of type IIC sPLA2. (C) Supernatants of Sf9 
cells expressing type IIA (lane 1) and type IIC (lane 2) sPLA2s were immunoblotted with the anti-type IIA sPLA2 antibody. (D) Supernatants 
of Sf9 cells expressing type IIA (open circles) and type IIC (closed circles) sPLA2s were incubated with the indicated amounts of anti-type IIA 
sPLA2 antibody for 1 h. After precipitation with protein-A Sepharose (Pharmacia), PLA2 activities remaining in the supernatants were meas-
ured. A representative result of three independent experiments is shown. 
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sPLA2 , may be a true effector of arachidonate metabolism 
even in B M M C expressing type IIA sPLA 2 . 
Type IIA, I IC and V SPLA2S are closely related to one 
another and m a p to the same chromosome locus [14,19], im-
plying their functional redundancy. In view of our previous 
finding that BALB/cJ-derived B M M C express m R N A for 
type I IC sPLA2 [6] (Fig. 4), we examined the identity of 
C57BL/6J-derived B M M C sPLA 2 with the recombinant type 
I IC enzyme. Although type IIC sPLA2 showed C a
2 + and p H 
dependence similar to that of C57BL/6J-derived B M M C 
sPLA2 , no crossreactivity of the anti-type IIA sPLA2 antibody 
with type IIC sPLA2 was observed (Fig. 3), indicating that 
C57BL/6J-derived B M M C sPLA2 may be distinct from type 
I IC sPLA2 . This conclusion is further supported by the ob-
servation that type I IC sPLA2 transcript was detectable only 
minimally in C57BL/6J-derived B M M C (data not shown) [16] 
and its expression in BALB/cJ-derived B M M C was not corre-
lated with P G D 2 generation [6]. 
We have found that type V sPLA2 was expressed in B M M C 
(Fig. 4). During the course of this study, Reddy et al. [16] 
have also reported that type V sPLA2 is expressed in various 
mouse mast cells, including those derived from type IIA 
sPLA2-deficient C57BL/6J mice, and is crucial for the regula-
tion of arachidonate metabolism. Although the contribution 
of type V sPLA2 was confined to immediate, but not delayed, 
P G D 2 generation in the mast cell lines they used [16], it is at 
present unclear whether the delayed P G D 2 generation ob-
served in primary B M M C , which Bingham et al. [9] and our 
group have studied, also depends on type V sPLA 2 . Of note, 
whereas Reddy et al. [16] failed to detect the transcripts for 
type I IA and I IC sPLA2s in their mast cells, these transcripts 
were readily detectable in our BALB/cJ-derived B M M C (Fig. 
4). Moreover, these three sPLA2s were also detected in rat 
mastocytoma RBL-2H3 (Fig. 4). The distinct profiles of 
sPLA2 expression might reflect the heterogeneity of mast cells, 
which is highly affected by microenvironments during culture. 
Indeed, type IIA, but not IIC, sPLA2 expression was greatly 
induced in BALB/cJ-derived B M M C when cultured with K L 
in combination with IL-10 and IL-1(3 [6,9]. Although these 
observations suggest that sPLA2 detected in C57BL/6J-de-
rived B M M C in this study is identical to type V sPLA2 , the 
final conclusion will have to be awaited until the enzymatic 
properties of recombinant type V sPLA2 , such as immuno-
reactivity and p H dependence, are compared with the present 
results. Also, it will be of interest to examine the cytokine 
regulation of type V sPLA2 expression in B M M C . Neverthe-
less, type V sPLA2 has also been implicated in P G E 2 gener-
ation in P388Di mouse macrophage-like cells, in which type 
IIA sPLA2 expression is barely detectable [18], and therefore 
is emerging as a novel effector involved in arachidonate-medi-
ated signal transduction. 
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